



State-of-the-Art Drug Discovery in the USA

Guest Editor:

Prof. Dr. Sarfaraz K. Niazi

College of Pharmacy, University
of Illinois, Chicago, IL 60612, USA

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

Dear Colleagues,

Modes of drug discovery shift over time; the new path engages digital technologies, AI drug design, modeling-based safety, and efficacy determination. The class of new drugs now comprises biological proteins, gene and cell therapy, and gene editing. mRNA vaccines and protein translation is changing the scope, returning the delivery to body cells instead of pills and injections. The AlphaFold capability to predict most complex structures, including proteins and receptors, will facilitate the creation of new drugs that had no treatment, such as the autoimmune disorders.

Therefore, we invite all authors actively contributing to drug discovery and development in the USA to participate in this Special Issue. Original research articles and reviews dealing with new strategies with the potential to provide novel treatments in the short term will be welcomed, as will manuscripts dealing with the hottest topics in drug discovery and cutting-edge methodological advances, including emerging industry trends and strategies in relationship with recent drug approvals.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)